133 related articles for article (PubMed ID: 27416700)
21. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
de Bazelaire C; Alsop DC; George D; Pedrosa I; Wang Y; Michaelson MD; Rofsky NM
Clin Cancer Res; 2008 Sep; 14(17):5548-54. PubMed ID: 18765547
[TBL] [Abstract][Full Text] [Related]
22. Editorial comment.
Akhtar NH; Tagawa ST
J Urol; 2011 Jan; 185(1):59. PubMed ID: 21074812
[No Abstract] [Full Text] [Related]
23. Rational therapy for renal cell carcinoma based on its genetic targets.
Messer J; Drabick J; Kaag M
Adv Exp Med Biol; 2013; 779():291-308. PubMed ID: 23288645
[TBL] [Abstract][Full Text] [Related]
24. [Research impulses for personalized cancer therapies].
Aktuelle Urol; 2013 Sep; 44(5):349. PubMed ID: 24043531
[No Abstract] [Full Text] [Related]
25. [Imaging of Metastastic Renal Cell Carcinoma under Therapy with Immune Checkpoint Inhibitors].
Notohamiprodjo M; Kopp HG; Bedke J
Rofo; 2017 Apr; 189(4):287-292. PubMed ID: 28335045
[No Abstract] [Full Text] [Related]
26. Decade in review-kidney cancer: discoveries, therapies and opportunities.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2014 Nov; 11(11):614-6. PubMed ID: 25287783
[TBL] [Abstract][Full Text] [Related]
27. [Systemic therapy for metastatic renal cell carcinoma].
Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
[TBL] [Abstract][Full Text] [Related]
28. From theoretical synergy to clinical supra-additive toxicity.
Soria JC; Massard C; Izzedine H
J Clin Oncol; 2009 Mar; 27(9):1359-61. PubMed ID: 19224836
[No Abstract] [Full Text] [Related]
29. Exceptional Response to Nivolumab Rechallenge in Metastatic Renal Cell Carcinoma with Parallel Changes in Genomic Profile.
Dizman N; Bergerot P; Bergerot C; Lanman RB; Raymond VM; Banks KC; Jones J; Pal SK
Eur Urol; 2018 Feb; 73(2):308-310. PubMed ID: 28844598
[No Abstract] [Full Text] [Related]
30. Duration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.
Négrier S
Oncology; 2012; 82(4):189-96. PubMed ID: 22440948
[TBL] [Abstract][Full Text] [Related]
31. Resistance to angiogenesis inhibitors in renal cell carcinoma.
Tamaskar I; Dhillon J; Pili R
Clin Adv Hematol Oncol; 2011 Feb; 9(2):101-10. PubMed ID: 22173604
[TBL] [Abstract][Full Text] [Related]
32. [Second-line treatment of advanced renal cell carcinoma after first-line targeted therapy].
Tomita Y
Gan To Kagaku Ryoho; 2011 Jun; 38(6):907-10. PubMed ID: 21677480
[TBL] [Abstract][Full Text] [Related]
33. Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Powles T
Clin Genitourin Cancer; 2012 Jun; 10(2):67-8. PubMed ID: 22608779
[No Abstract] [Full Text] [Related]
34. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
35. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
36. Bevacizumab as first-line therapy for patients with brain metastases from renal carcinoma: a case series.
Zustovich F; Ferro A; Farina P
Clin Genitourin Cancer; 2014 Jun; 12(3):e107-10. PubMed ID: 24583162
[No Abstract] [Full Text] [Related]
37. [Biomarker for molecular targeting therapy against renal cell carcinoma].
Mizuno R; Oya M
Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
[No Abstract] [Full Text] [Related]
38. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
39. Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma.
Yamamoto K; Yano I
Med Oncol; 2018 Jan; 35(2):16. PubMed ID: 29302760
[TBL] [Abstract][Full Text] [Related]
40. Contemporary treatment of metastatic renal cell carcinoma.
Wiechno P; Kucharz J; Sadowska M; Michalski W; Sikora-Kupis B; Jonska-Gmyrek J; Poniatowska G; Nietupski K; Ossolinski K; Demkow T
Med Oncol; 2018 Oct; 35(12):156. PubMed ID: 30368624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
